Literature DB >> 25599306

Identifying specific profiles in patients with different degrees of painful knee osteoarthritis based on serological biochemical and mechanistic pain biomarkers: a diagnostic approach based on cluster analysis.

Line Lindhardt Egsgaard1, Thomas Navndrup Eskehave, Anne C Bay-Jensen, Hans Christian Hoeck, Lars Arendt-Nielsen.   

Abstract

Biochemical and pain biomarkers can be applied to patients with painful osteoarthritis profiles and may provide more details compared with conventional clinical tools. The aim of this study was to identify an optimal combination of biochemical and pain biomarkers for classification of patients with different degrees of knee pain and joint damage. Such profiling may provide new diagnostic and therapeutic options. A total of 216 patients with different degrees of knee pain (maximal pain during the last 24 hours rated on a visual analog scale [VAS]) (VAS 0-100) and 64 controls (VAS 0-9) were recruited. Patients were separated into 3 groups: VAS 10 to 39 (N = 81), VAS 40 to 69 (N = 70), and VAS 70 to 100 (N = 65). Pressure pain thresholds, temporal summation to pressure stimuli, and conditioning pain modulation were measured from the peripatellar and extrasegmental sites. Biochemical markers indicative for autoinflammation and immunity (VICM, CRP, and CRPM), synovial inflammation (CIIIM), cartilage loss (CIIM), and bone degradation (CIM) were analyzed. WOMAC, Lequesne, and pain catastrophizing scores were collected. Principal component analysis was applied to select the optimal variable subset, and cluster analysis was applied to this subset to create distinctly different knee pain profiles. Four distinct knee pain profiles were identified: profile A (N = 27), profile B (N = 59), profile C (N = 85), and profile D (N = 41). Each knee pain profile had a unique combination of biochemical markers, pain biomarkers, physical impairments, and psychological factors that may provide the basis for mechanism-based diagnosis, individualized treatment, and selection of patients for clinical trials evaluating analgesic compounds. These results introduce a new profiling for knee OA and should be regarded as preliminary.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25599306     DOI: 10.1016/j.pain.0000000000000011

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  19 in total

Review 1.  A critical evaluation of validity and utility of translational imaging in pain and analgesia: Utilizing functional imaging to enhance the process.

Authors:  Jaymin Upadhyay; Christian Geber; Richard Hargreaves; Frank Birklein; David Borsook
Journal:  Neurosci Biobehav Rev       Date:  2017-08-12       Impact factor: 8.989

2.  Distinct tribological endotypes of pathological human synovial fluid reveal characteristic biomarkers and variation in efficacy of viscosupplementation at reducing local strains in articular cartilage.

Authors:  R M Irwin; E Feeney; C Secchieri; D Galesso; I Cohen; F Oliviero; R Ramonda; L J Bonassar
Journal:  Osteoarthritis Cartilage       Date:  2020-02-24       Impact factor: 6.576

Review 3.  Is osteoarthritis one disease or a collection of many?

Authors:  Leticia A Deveza; Richard F Loeser
Journal:  Rheumatology (Oxford)       Date:  2018-05-01       Impact factor: 7.580

4.  The C-reactive protein level after total knee arthroplasty is gender specific.

Authors:  Christoph Windisch; Steffen Brodt; Eric Roehner; Georg Matziolis
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2016-08-17       Impact factor: 4.342

Review 5.  Altered Central Sensitization and Pain Modulation in the CNS in Chronic Joint Pain.

Authors:  Lars Arendt-Nielsen; Søren T Skou; Thomas A Nielsen; Kristian K Petersen
Journal:  Curr Osteoporos Rep       Date:  2015-08       Impact factor: 5.096

Review 6.  A Mechanism-Based Approach to the Management of Osteoarthritis Pain.

Authors:  Ezra Cohen; Yvonne C Lee
Journal:  Curr Osteoporos Rep       Date:  2015-12       Impact factor: 5.096

7.  Pain Susceptibility Phenotypes in Those Free of Knee Pain With or at Risk of Knee Osteoarthritis: The Multicenter Osteoarthritis Study.

Authors:  Lisa C Carlesso; Neil A Segal; Laura Frey-Law; Yuqing Zhang; Lu Na; Michael Nevitt; Core E Lewis; Tuhina Neogi
Journal:  Arthritis Rheumatol       Date:  2019-02-07       Impact factor: 10.995

Review 8.  Phenotypes of osteoarthritis: current state and future implications.

Authors:  Leticia A Deveza; Amanda E Nelson; Richard F Loeser
Journal:  Clin Exp Rheumatol       Date:  2019-10-15       Impact factor: 4.473

Review 9.  The Potential Role of Sensory Testing, Skin Biopsy, and Functional Brain Imaging as Biomarkers in Chronic Pain Clinical Trials: IMMPACT Considerations.

Authors:  Shannon M Smith; Robert H Dworkin; Dennis C Turk; Ralf Baron; Michael Polydefkis; Irene Tracey; David Borsook; Robert R Edwards; Richard E Harris; Tor D Wager; Lars Arendt-Nielsen; Laurie B Burke; Daniel B Carr; Amy Chappell; John T Farrar; Roy Freeman; Ian Gilron; Veeraindar Goli; Juergen Haeussler; Troels Jensen; Nathaniel P Katz; Jeffrey Kent; Ernest A Kopecky; David A Lee; William Maixner; John D Markman; Justin C McArthur; Michael P McDermott; Lav Parvathenani; Srinivasa N Raja; Bob A Rappaport; Andrew S C Rice; Michael C Rowbotham; Jeffrey K Tobias; Ajay D Wasan; James Witter
Journal:  J Pain       Date:  2017-02-27       Impact factor: 5.820

Review 10.  Patient phenotyping in clinical trials of chronic pain treatments: IMMPACT recommendations.

Authors:  Robert R Edwards; Robert H Dworkin; Dennis C Turk; Martin S Angst; Raymond Dionne; Roy Freeman; Per Hansson; Simon Haroutounian; Lars Arendt-Nielsen; Nadine Attal; Ralf Baron; Joanna Brell; Shay Bujanover; Laurie B Burke; Daniel Carr; Amy S Chappell; Penney Cowan; Mila Etropolski; Roger B Fillingim; Jennifer S Gewandter; Nathaniel P Katz; Ernest A Kopecky; John D Markman; George Nomikos; Linda Porter; Bob A Rappaport; Andrew S C Rice; Joseph M Scavone; Joachim Scholz; Lee S Simon; Shannon M Smith; Jeffrey Tobias; Tina Tockarshewsky; Christine Veasley; Mark Versavel; Ajay D Wasan; Warren Wen; David Yarnitsky
Journal:  Pain       Date:  2016-09       Impact factor: 7.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.